Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by mattw1100on Mar 19, 2018 2:56pm

126 Views

Post# 27741438

RE:RE:RE:RE:RE:RE:Article in Montreal newspaper La Presse

The stock price goes up, wayyy up. At 5000 patients (avg per year) we would have an EPS of around $3.25 CAD. At 8000 patients (ave per year) we would have an EPS of $5.20 CAD. This is using an exchange rate of $1.20 CAD/USD and the net price of $84,600 USD and no dilution of shares, 75M. Put 20x multiples on these numbers or be more conservative and use 1500 patients = .97 EPS still puts us at $20 per share with fundamentals driving the stock. I can't wait till Q4 2018 or Q1 2019 when we have a better understanding of just how successful this product will be. Can't deny the risk/reward potential on TH got a lot better on approval day. We are undervalued and are in for a nice ride ahead.

Bullboard Posts

Nextech CEO provides company update on Amazon deal and more